Skip to main content

Study

New Hydrogel Cream Helps Soothe Eczema for Older Adults

A new cream using hydrogels and fusidic acid shows promise in easing eczema symptoms while keeping skin hydrated.

Skin & Hair HealthHealthy AgingWomen's HealthMen's Health
Study Credibility: Low3.1/10Early findingsNot enough evidence yetTalk with your clinician
PublishedSep 2025Last reviewedOct 2026
Email this

Summary

In plain language

Researchers have developed a new cream using hydrogels combined with fusidic acid to help treat eczema, a common skin condition that causes itchy and inflamed patches. This innovative cream not only targets the bacterial infections often associated with eczema but also keeps the skin moist and protected. This is especially important for seniors, as keeping skin hydrated can aid in faster healing and comfort. The study found that this hydrogel-based cream maintains its stability and effectiveness over time, making it a potentially reliable option for managing eczema symptoms. Seniors dealing with dry, itchy skin might find this new approach beneficial and should discuss it with their healthcare providers.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

This study explored a new way to manage eczema using a cream made from hydrogels and fusidic acid.

  • Researchers created a special cream by combining hydrogels, known for their high water absorption, with fusidic acid, an antibiotic that helps fight bacteria associated with eczema.

  • They found that this combination keeps the skin moist and the cream remains stable and effective for at least 28 days, making it a promising option for long-term use.

  • While the study showed positive results, it's important to remember that individual responses can vary, and the findings need to be confirmed by further research.

Seniors experiencing eczema should consider discussing this new treatment option with their healthcare providers to determine if it might be suitable for them.

Research Quality Score

Scored October 15, 2026 using rubric mq-1.8_2026-07-06.

Assessment

The study is a preclinical experimental research focusing on hydrogel development for eczema treatment. It lacks bias control measures like randomization and blinding, typical for preclinical studies. Statistical methods are standard but lack power analysis. Transparency is moderate with detailed methods but no pre-registration. No conflicts of interest were disclosed, impacting the conflicts score. The study is relevant to the target population of older adults with eczema. Published in a Tier 3 journal, it has moderate journal quality.

Category Breakdown

CategoryScoreRating
Study design3.3/10
Bias control0.0/10
Statistical methods5.0/10
Reporting completeness5.0/10
Conflicts & funding0.0/10
Replication0.0/10
Relevance to chosen population10.0/10
Journal Reliability5.0/10

Additional Notes

The study develops and evaluates hydrogels containing HEMA, Eudragit L-100, and fusidic acid for eczema treatment. It characterizes the hydrogels and cream formulations using FTIR and SEM analyses, assessing stability and swelling efficiency.

Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were checked.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.